<DOC>
	<DOCNO>NCT00941811</DOCNO>
	<brief_summary>The occurance clinical course human papillomavirus ( HPV ) -induced lesion largely determined nature cellular immune defense generate . Even tough genital wart vulvar intraepithelial neoplasia ( VIN ) HPV-associated genital lesion differ risk malignant progression . Imiquimod ( IMQ ) topically apply Toll-like receptor ( TLR ) 7 agonist approve treatment superficial ( pre- ) carcinoma skin ( basal cell carcinoma , actinic keratosis ) HPV-associated lesion ( genital wart ) . It act activation immune system exert anti-tumor anti-viral property . The aim study evaluate mechanism IMQ treatment analyze difference HPV-affected non affected tissue cellular molecular level determine immunofluorescence staining real time PCR , respectively .</brief_summary>
	<brief_title>Immunevasion Human Papillomavirus ( HPV ) Vulvar Intraepithelial Neoplasia 2/3 Anogenital Warts Efficiency Mechanisms Imiquimod Treatment</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma Situ</mesh_term>
	<mesh_term>Imiquimod</mesh_term>
	<criteria>Female patient histologically proven Vulvar Intraepithelial Neoplasia 2/3 and/or anogenital Condyloma acuminata Age 1850 Informed consent Malignancy Pregnancy Therapeutic Immunosupression Severe systemic dermatologic disease</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>